Literature DB >> 21278176

Incidence and survival outcome following femoral artery reconstruction during endovascular abdominal aortic aneurysm repair.

Christopher P Twine1, Andrew Wood, Andrew Gordon, Susan Hill, Richard Whiston, Ian M Williams.   

Abstract

BACKGROUND: Planned or unplanned reconstruction of the common femoral artery (femoro-femoral crossover and/or patch closure) may be required following endovascular abdominal aortic aneurysm repair (EVAR) stent graft deployment for arterial closure or maintenance of limb perfusion. The aim of this study was to examine the incidence of common femoral artery reconstruction (FAR) following EVAR and examine the effect on patient survival.
METHODS: A total of 178 patients undergoing EVAR were studied retrospectively.
RESULTS: In all, 31 patients (17.4%) underwent FAR; 16 (51.6%) femoro-femoral crossover, and 15 (48.4%) endarterectomy and patch closure. All cause survival in patients undergoing FAR was significantly poorer than those undergoing direct closure (P = .010).A total of 3 factors: the need for FAR (hazard ratio [HR] = 0.435, P = .006), chronic obstructive pulmonary disease ([COPD] HR = 0.424, P = .002), and abdominal aortic aneurysm (AAA) size (HR = 1.414, P = .005) were significantly and independently associated with survival on forward conditional analysis.
CONCLUSIONS: Femoral artery reconstruction was performed in almost 1 in 5 patients undergoing EVAR and associated with decreased survival. Multidisciplinary teams should be aware of these findings when planning EVAR, especially in borderline candidates.

Entities:  

Mesh:

Year:  2011        PMID: 21278176     DOI: 10.1177/1538574410396591

Source DB:  PubMed          Journal:  Vasc Endovascular Surg        ISSN: 1538-5744            Impact factor:   1.089


  1 in total

1.  The impact of concomitant procedures during endovascular abdominal aortic aneurysm repair on perioperative outcomes.

Authors:  Klaas H J Ultee; Sara L Zettervall; Peter A Soden; Jeremy Darling; Jeffrey J Siracuse; Matthew J Alef; Hence J M Verhagen; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2016-03-16       Impact factor: 4.268

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.